vs
Amphastar Pharmaceuticals, Inc.（AMPH）与世纪互联（VNET）财务数据对比。点击上方公司名可切换其他公司
世纪互联的季度营收约是Amphastar Pharmaceuticals, Inc.的2.0倍（$362.7M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -10.7%，领先24.0%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $-193.1M），过去两年世纪互联的营收复合增速更高（17.4% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
VNET Group即世纪互联，是中国领先的第三方中立数据中心服务商，提供机柜托管、云基础设施、混合云部署及网络管理等解决方案，服务覆盖科技、金融、零售等多领域企业客户，为企业数字化运营提供稳定的算力与网络支撑。
AMPH vs VNET — 直观对比
营收规模更大
VNET
是对方的2.0倍
$183.1M
净利率更高
AMPH
高出24.0%
-10.7%
自由现金流更多
AMPH
多$217.7M
$-193.1M
两年增速更快
VNET
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $362.7M |
| 净利润 | $24.4M | $-38.7M |
| 毛利率 | 46.8% | 20.9% |
| 营业利润率 | 19.4% | 0.5% |
| 净利率 | 13.3% | -10.7% |
| 营收同比 | -1.8% | — |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHVNET
| Q4 25 | $183.1M | — | ||
| Q3 25 | $191.8M | $362.7M | ||
| Q2 25 | $174.4M | — | ||
| Q1 25 | $170.5M | $309.5M | ||
| Q4 24 | $186.5M | — | ||
| Q3 24 | $191.2M | $302.2M | ||
| Q2 24 | $182.4M | $274.4M | ||
| Q1 24 | $171.8M | $262.9M |
净利润AMPHVNET
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-38.7M | ||
| Q2 25 | $31.0M | — | ||
| Q1 25 | $25.3M | $-2.4M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-2.1M | ||
| Q2 24 | $37.9M | $-1.1M | ||
| Q1 24 | $43.2M | $-22.0M |
毛利率AMPHVNET
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | 20.9% | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | 25.2% | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | 23.2% | ||
| Q2 24 | 52.2% | 21.3% | ||
| Q1 24 | 52.4% | 21.6% |
营业利润率AMPHVNET
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | 0.5% | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 21.9% | 0.1% | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | 24.5% | ||
| Q2 24 | 30.3% | 0.2% | ||
| Q1 24 | 27.9% | 0.2% |
净利率AMPHVNET
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -10.7% | ||
| Q2 25 | 17.8% | — | ||
| Q1 25 | 14.8% | -0.8% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -0.7% | ||
| Q2 24 | 20.8% | -0.4% | ||
| Q1 24 | 25.1% | -8.4% |
每股收益（稀释后）AMPHVNET
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $492.1M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $890.8M |
| 总资产 | $1.6B | $6.1B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHVNET
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | $492.1M | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | $544.3M | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | $219.5M | ||
| Q2 24 | $217.8M | $247.2M | ||
| Q1 24 | $289.6M | $246.9M |
总债务AMPHVNET
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | $1.2B | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHVNET
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | $890.8M | ||
| Q2 25 | $757.5M | — | ||
| Q1 25 | $751.3M | $927.8M | ||
| Q4 24 | $732.3M | — | ||
| Q3 24 | $727.7M | $902.9M | ||
| Q2 24 | $713.3M | $900.6M | ||
| Q1 24 | $672.4M | $895.1M |
总资产AMPHVNET
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $6.1B | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.6B | $5.4B | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $4.3B | ||
| Q2 24 | $1.5B | $4.0B | ||
| Q1 24 | $1.6B | $3.9B |
负债/权益比AMPHVNET
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | 1.28× | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $113.8M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-193.1M |
| 自由现金流率自由现金流/营收 | 13.4% | -53.2% |
| 资本支出强度资本支出/营收 | 4.5% | 84.6% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $-589.7M |
8季度趋势，按日历期对齐
经营现金流AMPHVNET
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | $113.8M | ||
| Q2 25 | $35.6M | — | ||
| Q1 25 | $35.1M | $27.0M | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $60.0M | $108.3M | ||
| Q2 24 | $69.1M | $55.8M | ||
| Q1 24 | $55.3M | $37.1M |
自由现金流AMPHVNET
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | $-193.1M | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | $-220.0M | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | $-95.0M | ||
| Q2 24 | $63.1M | $-81.6M | ||
| Q1 24 | $46.5M | $-102.2M |
自由现金流率AMPHVNET
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | -53.2% | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | -71.1% | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | -31.4% | ||
| Q2 24 | 34.6% | -29.8% | ||
| Q1 24 | 27.1% | -38.9% |
资本支出强度AMPHVNET
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | 84.6% | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | 79.8% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | 67.3% | ||
| Q2 24 | 3.3% | 50.1% | ||
| Q1 24 | 5.1% | 53.0% |
现金转化率AMPHVNET
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
VNET
暂无分部数据
